Alternative endpoints to mortality in cancer screening trials
Molecular Oncology · 2024
DOI: 10.1002/1878-0261.13697 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Oncology, 2024. Verfasst von Sir Harpal Kumar. Beteiligte Einrichtung: BioPharma Business & Europe, GRAIL Bio UK Ltd., London, UK. Hauptthemen laut MEDLINE: Early Detection of Cancer, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The reliance on mortality endpoints in cancer screening trials is not always compatible with the need to accelerate progress in outcomes for patient and public benefit. Evaluation of novel cancer screening technologies, such as multi‐cancer early detection (MCED) tests, could be expedited by using alternative metrics that are measurable earlier than mortality. These include endpoints based on cancer stage at diagnosis, such as reduction in late‐stage cancer incidence, and endpoints following cancer diagnosis, such as eligibility for curative therapy. Innovative trial designs with earlier measures that complement cancer mortality are needed to realise the potential benefits of novel screening technologies such as MCEDs more rapidly.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- BioPharma Business & Europe, GRAIL Bio UK Ltd., London, UK.
Zitieren
APA
Kumar, S. H. (2024). Alternative endpoints to mortality in cancer screening trials. Molecular Oncology. https://doi.org/10.1002/1878-0261.13697
Vancouver
Kumar SH. Alternative endpoints to mortality in cancer screening trials. Molecular Oncology. 2024. doi:10.1002/1878-0261.13697
BibTeX
@article{Kumar2024,
author = {Kumar, Sir Harpal},
title = {Alternative endpoints to mortality in cancer screening trials},
journal = {Molecular Oncology},
year = {2024},
doi = {10.1002/1878-0261.13697}
}
EUVIMED